Literature DB >> 16585909

[A motor function measurement scale for neuromuscular diseases - description and validation study].

C Bérard1, C Payan, J Fermanian, F Girardot.   

Abstract

A new scale for motor function measurement has been developed for neuromuscular diseases. After the study of a preliminary and a first version, the validation study included 303 patients, aged 6 to 62 years. Seventy-two patients had Duchenne muscular dystrophy, 32 Becker muscular dystrophy, 30 limb-girdle muscular dystrophy, 39 facio-scapulo-humeral dystrophy, 29 myotonic dystrophy, 21 congenital myopathy, 10 congenital muscular dystrophy, 35 spinal muscular atrophy and 35 hereditary neuropathy. The sensitivity for change was evaluated with 152 patients one year after. The scale comprised 32 items, in three dimensions: standing position and transfers, axial and proximal motor function, distal motor function. High correlations (>0.80) were found between the total score and other scores: Vignos and Brooke grades, Functional Independence Measure, the global severity of disability evaluated with visual analog scales by physicians and physiotherapists. This scale is reliable, does not require any special equipment and is well accepted by patients. It takes an average of 36 min (range 8-75) to complete the scale. Preliminary results of the second evaluation showed good sensitivity to change since last visit, considering rating by patient, investigator or physiotherapist. Also, significant differences in scores are obtained with the greatest deterioration observed in Duchenne patients.

Entities:  

Mesh:

Year:  2006        PMID: 16585909     DOI: 10.1016/s0035-3787(06)75039-1

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  10 in total

1.  Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design.

Authors:  P Kaufmann; F Muntoni
Journal:  Neuromuscul Disord       Date:  2007-02-14       Impact factor: 4.296

2.  Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

Authors:  Chadi Abbara; Brigitte Estournet; Lucette Lacomblez; Benedicte Lelièvre; Amal Ouslimani; Blandine Lehmann; Louis Viollet; Annie Barois; Bertrand Diquet
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Reliability, validity and description of timed performance of the Jebsen-Taylor Test in patients with muscular dystrophies.

Authors:  Mariana Cunha Artilheiro; Francis Meire Fávero; Fátima Aparecida Caromano; Acary de Souza Bulle Oliveira; Nelson Carvas; Mariana Callil Voos; Cristina Dos Santos Cardoso de Sá
Journal:  Braz J Phys Ther       Date:  2017-12-08       Impact factor: 3.377

4.  Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study.

Authors:  Merel Jansen; Imelda Jm de Groot; Nens van Alfen; Alexander Ch Geurts
Journal:  BMC Pediatr       Date:  2010-08-06       Impact factor: 2.125

5.  Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?

Authors:  J W Witherspoon; R Vasavada; R H Logaraj; M Waite; J Collins; C Shieh; K Meilleur; C Bönnemann; M Jain
Journal:  Eur J Paediatr Neurol       Date:  2018-10-23       Impact factor: 3.140

6.  Different trajectories in upper limb and gross motor function in spinal muscular atrophy.

Authors:  Giorgia Coratti; Maria Carmela Pera; Jacqueline Montes; Amy Pasternak; Mariacristina Scoto; Giovanni Baranello; Sonia Messina; Sally Dunaway Young; Allan M Glanzman; Tina Duong; Roberto De Sanctis; Elena Stacy Mazzone; Evelin Milev; Annemarie Rohwer; Matthew Civitello; Marika Pane; Laura Antonaci; Anna Lia Frongia; Maria Sframeli; Gian Luca Vita; Adele DʼAmico; Irene Mizzoni; Emilio Albamonte; Basil T Darras; Enrico Bertini; Valeria A Sansone; Francesca Bovis; John Day; Claudio Bruno; Francesco Muntoni; Darryl C De Vivo; Richard Finkel; Eugenio Mercuri
Journal:  Muscle Nerve       Date:  2021-08-09       Impact factor: 3.852

7.  A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment.

Authors:  Anne-Gaëlle Le Moing; Andreea Mihaela Seferian; Amélie Moraux; Mélanie Annoussamy; Eric Dorveaux; Erwan Gasnier; Jean-Yves Hogrel; Thomas Voit; David Vissière; Laurent Servais
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

8.  Patients with Duchenne and Becker muscular dystrophies are not more asymmetrical than healthy controls on timed performance of upper limb tasks.

Authors:  M C Artilheiro; C S C Sá; F M Fávero; F A Caromano; M C Voos
Journal:  Braz J Med Biol Res       Date:  2017-07-24       Impact factor: 2.590

9.  Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).

Authors:  Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Bart Bartels; Fay-Lynn Asselman; Louise A M Otto; H Stephan Goedee; Laura E Habets; Janke F de Groot; Marja A G C Schoenmakers; Inge Cuppen; Leonard H van den Berg; W Ludo van der Pol
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

Review 10.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.